(Q39694574)

14 September 2017

title

Glatiramer acetate antibodies, gene expression and disease activity in multiple sclerosis (English)

1 reference

14 September 2017

0 references

1 reference

Per Soelberg Sørensen

8

object named as

P S Sørensen

1 reference

14 September 2017

F Sellebjerg

1

1 reference

14 September 2017

C J Hedegaard

2

1 reference

14 September 2017

M Krakauer

3

1 reference

14 September 2017

D Hesse

4

1 reference

14 September 2017

H Lund

5

1 reference

14 September 2017

C H Nielsen

6

1 reference

14 September 2017

H B Søndergaard

7

1 reference

14 September 2017

publication date

21 October 2011

1 reference

Multiple Sclerosis Journal

14 September 2017

published in

1 reference

14 September 2017

volume

18

1 reference

14 September 2017

issue

3

1 reference

14 September 2017

page(s)

305-313

1 reference

Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action

14 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1352458511420268

The mechanism of action of glatiramer acetate treatment in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511420268

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511420268

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511420268

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511420268

Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511420268

Treatment with glatiramer acetate induces specific IgG4 antibodies in multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511420268

Long-term treatment of multiple sclerosis with glatiramer acetate: natural history of the subtypes of anti-glatiramer acetate antibodies and their correlation with clinical efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511420268

Blocking effects of serum reactive antibodies induced by glatiramer acetate treatment in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511420268

Human B cell clones can be induced to proliferate and to switch to IgE and IgG4 synthesis by interleukin 4 and a signal provided by activated CD4+ T cell clones

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511420268

Correlation of serum IL-13 and IL-5 levels with clinical response to Glatiramer acetate in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511420268

Gene expression analysis of interferon-beta treatment in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511420268

Identification of new sensitive biomarkers for the in vivo response to interferon-beta treatment in multiple sclerosis using DNA-array evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511420268

Differentiation of effector CD4 T cell populations (*)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511420268

Interferon beta results in immediate reduction of contrast-enhanced MRI lesions in multiple sclerosis patients followed by weekly MRI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511420268

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511420268

Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511420268

Immunological assay for assessing the efficacy of glatiramer acetate (Copaxone) in multiple sclerosis. A pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511420268

The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511420268

Using measurements of neutralizing antibodies: the challenge of IFN-beta therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511420268

Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511420268

Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511420268

Increased expression of B cell-associated regulatory cytokines by glatiramer acetate in mice with experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511420268

21 January 2018

Identifiers

DOI

10.1177/1352458511420268

1 reference

14 September 2017

1 reference